|
|
|
Originator Org.- |
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项评价注射用 Oba01 在局部晚期/转移性 DR5 阳性非小细胞肺癌患者中的安全性、耐受性、药代动力学特征和初步疗效的 I 期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Oba01 for injection in patients with locally advanced/metastatic DR5-positive non-small cell lung cancer
主要目的:评价 Oba01 在局部晚期/转移性非小细胞肺癌患者中的安全性及耐受性,并探索剂量限制性毒性(DLT)和最大耐受剂量(MTD),为 II 期临床试验推荐给药剂量(RP2D)的确定提供依据。
[Translation] Primary objective: To evaluate the safety and tolerability of Oba01 in patients with locally advanced/metastatic non-small cell lung cancer, and to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), so as to provide a basis for determining the recommended dose (RP2D) for Phase II clinical trials.
100 Clinical Results associated with Yantai Heyuan Aidis Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Yantai Heyuan Aidis Biomedical Technology Co., Ltd.
100 Deals associated with Yantai Heyuan Aidis Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Yantai Heyuan Aidis Biomedical Technology Co., Ltd.